Vivos Therapeutics (VVOS) Total Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Total Non-Current Liabilities data on file, last reported at $25.0 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $25.0 million in Q1 2026; TTM through Mar 2026 was $25.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $25.4 million, changed N/A from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $25.0 million, down from $25.4 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for VVOS reached as high as $25.4 million in Q4 2025 and fell as low as $8.4 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $16.1 million across 4 years, with a median of $14.9 million in 2023.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 4.38% in 2023 and fell as far as 4.38% in 2023.
• Year by year, Total Non-Current Liabilities stood at $8.4 million in 2022, then gained by 15.14% to $9.7 million in 2023, then surged by 162.66% to $25.4 million in 2025, then dropped by 1.58% to $25.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $25.0 million in Q1 2026, $25.4 million in Q4 2025, and $21.7 million in Q3 2025.